vs
MACROGENICS INC（MGNX）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
RE/MAX Holdings, Inc.的季度营收约是MACROGENICS INC的1.7倍（$71.1M vs $41.2M），MACROGENICS INC同比增速更快（113.0% vs -1.8%），MACROGENICS INC自由现金流更多（$42.8M vs $33.5M），过去两年MACROGENICS INC的营收复合增速更高（112.8% vs -4.7%）
MacroGenics Inc是一家临床阶段生物制药公司，专注于研发针对癌症和自身免疫性疾病的新型免疫疗法，核心产品管线以单克隆抗体类治疗药物为核心，重点项目覆盖实体瘤与血液恶性肿瘤，通过与全球药企合作推进产品落地。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
MGNX vs RMAX — 直观对比
营收规模更大
RMAX
是对方的1.7倍
$41.2M
营收增速更快
MGNX
高出114.9%
-1.8%
自由现金流更多
MGNX
多$9.3M
$33.5M
两年增速更快
MGNX
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.2M | $71.1M |
| 净利润 | — | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | -29.3% | 13.1% |
| 净利率 | — | 2.0% |
| 营收同比 | 113.0% | -1.8% |
| 净利润同比 | — | -75.2% |
| 每股收益（稀释后） | $-0.23 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MGNXRMAX
| Q4 25 | $41.2M | $71.1M | ||
| Q3 25 | $72.8M | $73.2M | ||
| Q2 25 | $22.2M | $72.8M | ||
| Q1 25 | $13.2M | $74.5M | ||
| Q4 24 | $19.4M | $72.5M | ||
| Q3 24 | $110.7M | $78.5M | ||
| Q2 24 | $10.8M | $78.5M | ||
| Q1 24 | $9.1M | $78.3M |
净利润MGNXRMAX
| Q4 25 | — | $1.4M | ||
| Q3 25 | $16.8M | $4.0M | ||
| Q2 25 | $-36.3M | $4.7M | ||
| Q1 25 | $-41.0M | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $56.3M | $966.0K | ||
| Q2 24 | $-55.7M | $3.7M | ||
| Q1 24 | $-52.2M | $-3.4M |
毛利率MGNXRMAX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 98.8% | — | ||
| Q3 24 | 99.8% | — | ||
| Q2 24 | 98.4% | — | ||
| Q1 24 | 97.0% | — |
营业利润率MGNXRMAX
| Q4 25 | -29.3% | 13.1% | ||
| Q3 25 | 25.6% | 25.0% | ||
| Q2 25 | -165.3% | 19.3% | ||
| Q1 25 | -323.1% | 7.2% | ||
| Q4 24 | -273.0% | 5.9% | ||
| Q3 24 | 48.9% | 19.4% | ||
| Q2 24 | -538.9% | 20.6% | ||
| Q1 24 | -590.4% | 5.8% |
净利率MGNXRMAX
| Q4 25 | — | 2.0% | ||
| Q3 25 | 23.1% | 5.4% | ||
| Q2 25 | -163.0% | 6.4% | ||
| Q1 25 | -311.1% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | 50.9% | 1.2% | ||
| Q2 24 | -515.6% | 4.7% | ||
| Q1 24 | -573.3% | -4.3% |
每股收益（稀释后）MGNXRMAX
| Q4 25 | $-0.23 | — | ||
| Q3 25 | $0.27 | — | ||
| Q2 25 | $-0.57 | — | ||
| Q1 25 | $-0.65 | — | ||
| Q4 24 | $-0.24 | — | ||
| Q3 24 | $0.90 | — | ||
| Q2 24 | $-0.89 | — | ||
| Q1 24 | $-0.84 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $57.2M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $55.6M | $452.4M |
| 总资产 | $256.8M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资MGNXRMAX
| Q4 25 | $57.2M | $118.7M | ||
| Q3 25 | $80.1M | $107.5M | ||
| Q2 25 | $130.7M | $94.3M | ||
| Q1 25 | $145.6M | $89.1M | ||
| Q4 24 | $182.8M | $96.6M | ||
| Q3 24 | $179.6M | $83.8M | ||
| Q2 24 | $83.9M | $66.1M | ||
| Q1 24 | $80.4M | $82.1M |
总债务MGNXRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益MGNXRMAX
| Q4 25 | $55.6M | $452.4M | ||
| Q3 25 | $67.0M | $448.1M | ||
| Q2 25 | $46.6M | $442.4M | ||
| Q1 25 | $79.1M | $433.5M | ||
| Q4 24 | $116.1M | $429.5M | ||
| Q3 24 | $120.1M | $423.1M | ||
| Q2 24 | $57.8M | $418.4M | ||
| Q1 24 | $106.2M | $412.0M |
总资产MGNXRMAX
| Q4 25 | $256.8M | $582.5M | ||
| Q3 25 | $270.8M | $582.2M | ||
| Q2 25 | $245.4M | $574.8M | ||
| Q1 25 | $224.6M | $571.4M | ||
| Q4 24 | $261.7M | $581.6M | ||
| Q3 24 | $264.5M | $578.6M | ||
| Q2 24 | $201.1M | $571.4M | ||
| Q1 24 | $248.3M | $566.7M |
负债/权益比MGNXRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $43.0M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $42.8M | $33.5M |
| 自由现金流率自由现金流/营收 | 103.8% | 47.1% |
| 资本支出强度资本支出/营收 | 0.6% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-83.0M | $56.8M |
8季度趋势，按日历期对齐
经营现金流MGNXRMAX
| Q4 25 | $43.0M | $40.9M | ||
| Q3 25 | $-30.2M | $17.7M | ||
| Q2 25 | $-47.0M | $4.6M | ||
| Q1 25 | $-46.9M | $5.7M | ||
| Q4 24 | $-38.4M | $59.7M | ||
| Q3 24 | $60.2M | $17.6M | ||
| Q2 24 | $-44.5M | $15.9M | ||
| Q1 24 | $-45.6M | $9.4M |
自由现金流MGNXRMAX
| Q4 25 | $42.8M | $33.5M | ||
| Q3 25 | $-30.6M | $16.4M | ||
| Q2 25 | $-47.7M | $2.9M | ||
| Q1 25 | $-47.4M | $4.0M | ||
| Q4 24 | $-39.0M | $53.0M | ||
| Q3 24 | $59.6M | $16.3M | ||
| Q2 24 | $-45.5M | $14.0M | ||
| Q1 24 | $-47.1M | $6.8M |
自由现金流率MGNXRMAX
| Q4 25 | 103.8% | 47.1% | ||
| Q3 25 | -42.0% | 22.4% | ||
| Q2 25 | -214.5% | 4.0% | ||
| Q1 25 | -359.5% | 5.3% | ||
| Q4 24 | -201.7% | 73.2% | ||
| Q3 24 | 53.8% | 20.8% | ||
| Q2 24 | -421.6% | 17.8% | ||
| Q1 24 | -517.4% | 8.6% |
资本支出强度MGNXRMAX
| Q4 25 | 0.6% | 10.4% | ||
| Q3 25 | 0.6% | 1.8% | ||
| Q2 25 | 3.2% | 2.2% | ||
| Q1 25 | 4.0% | 2.3% | ||
| Q4 24 | 3.2% | 9.1% | ||
| Q3 24 | 0.5% | 1.7% | ||
| Q2 24 | 9.6% | 2.4% | ||
| Q1 24 | 16.0% | 3.3% |
现金转化率MGNXRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | -1.79× | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | 1.07× | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MGNX
| Revenue From Collaborative Agreements | $20.3M | 49% |
| Contract Manufacturing | $11.3M | 27% |
| Other | $9.7M | 23% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
